Corporate News & Publications

CLINUVEL's company releases, including archives.

Sunday, 27 November 2016 13:19

Managing Director's AGM Presentation

Melbourne, Australia and New York, US, 9 November 2016 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that it met on 7 November with the US Food and Drug Administration’s (FDA’s) Division of Dermatology and Dental Products (DDDP) to discuss the content and format of a new drug application (NDA) submission as part of the US regulatory pathway for CLINUVEL’s medicinal product SCENESSE® (afamelanotide 16mg). The pharmaceutical product has been developed for the treatment of erythropoietic protoporphyria (EPP)1, a rare genetic enzymatic disorder causing lifelong absolute light intolerance. The pre-NDA meeting allowed both parties to discuss…
Monday, 31 October 2016 14:16

Appendix 4C

Thursday, 27 October 2016 05:36

Appendix 4G

Monday, 24 October 2016 03:46

CLINUVEL relocates Melbourne office

Melbourne, Australia, October 24, 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY) today announced that its head office in Melbourne has relocated. The new address, which will also be the Company’s Registered Address, is: Level 6 15 Queen Street Melbourne Victoria, Australia, 3000 All telephone and fax numbers remain the same. - End - For more information contact: CLINUVEL PHARMACEUTICALS LTD T: +61 3 9660 4900 E: This email address is being protected from spambots. You need JavaScript enabled to view it. This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and…
Melbourne, Australia and Leatherhead, UK, 24 October 2016 The US Food and Drug Administration (FDA) will today host a scientific workshop on erythropoietic protoporphyria (EPP) at the FDA campus in Silver Spring. The workshop is open to all EPP stakeholders, with the FDA seeking perspective on EPP disease symptoms, its impact on daily life, experience with current treatment regimens for EPP, and aspects of clinical development of products intended to treat EPP. The meeting will also be available for viewing via webcast for those who have registered, and public online archive thereafter. CLINUVEL’s product SCENESSE® (afamelanotide 16mg) has been evaluated…
Wednesday, 26 October 2016 21:31

Annual Report for the year ended 30 June 2016

CLINUVEL's Annual Report for the year ended 30 June 2016.

Quick Links